newsCEPI calls for proposals to apply for COVID-19 vaccine funding7 May 2020 | By Victoria Rees (European Pharmaceutical Review)CEPI has announced it is urging organisations to apply for funding for the development and manufacturing of potential COVID-19 vaccines.
newsCEPI and European Investment Bank collaborate to fund vaccine projects5 May 2020 | By Victoria Rees (European Pharmaceutical Review)The Coalition for Epidemic Preparedness Innovations (CEPI) and European Investment Bank (EIB) will work together to identify and fund vaccine projects for infectious diseases.
newsWHO launches Access to COVID-19 Tools Accelerator30 April 2020 | By Victoria Rees (European Pharmaceutical Review)The World Health Organization (WHO) has launched its Access to COVID-19 Tools Accelerator, a collaboration to progress the development of coronavirus vaccines and therapeutics.
newsOpen letter calls for UK government to stop pharma profiting from COVID-1917 April 2020 | By Victoria Rees (European Pharmaceutical Review)An open letter from aid organisations and academics has called on the UK government to stipulate conditions for pharmaceutical companies using public funding for COVID-19 vaccines.
newsCEPI calls for $2bn of funding for coronavirus vaccine17 March 2020 | By Victoria Rees (European Pharmaceutical Review)According to CEPI, $2 billion is needed to progress coronavirus vaccines through development as quickly as possible, leading the organisation to call for donations.
newsUK government pledges £20m to CEPI for coronavirus vaccine research4 February 2020 | By Hannah Balfour (European Pharmaceutical Review)The UK Health Secretary announced the government will give Coalition for Epidemic Preparedness Innovations (CEPI) £20 million to research vaccines for the 2019 novel coronavirus (2019-nCoV).
newsCEPI announces three programmes to develop coronavirus vaccine27 January 2020 | By Victoria Rees (European Pharmaceutical Review)The CEPI has announced three respective projects with Inovio, the University of Queensland and Moderna, to develop a vaccine for the novel coronavirus, nCoV-2019.
